Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2026 (year ended September 2026) was $337.4 billion, up 5.00% from fiscal 2025.
- Revenue
- +5.52%
- EPS
- +258.4%
- Free cash flow
- −7.81%
- Total debt
- +47.1%
Quarter to September 2026, against a year earlier
Follow COR
Alert me
Cencora, Inc. (COR) P/E ratio
As of 5 November 2026, Cencora, Inc. (COR) trades at a P/E ratio of 18.8×. Over the past ten years it has ranged from 0.0× (September 2021) to 1,035× (March 2015); the current reading is higher than 48% of that period. That is below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 16.6× | (57.30%) |
| FY2025 | 39.0× | 31.24% |
| FY2024 | 29.7× | 42.77% |
| FY2023 | 20.8× | 25.11% |
| FY2022 | 16.6× | 4.11% |
| FY2021 | 16.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 20.2× | 65.68% |
| FY2018 | 12.2× | (72.15%) |
| FY2017 | 43.8× | 268.52% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 16.6× | (20.49%) |
| Jun 2026 | 20.9× | (12.58%) |
| Mar 2026 | 23.9× | (40.59%) |
| Dec 2025 | 40.3× | 3.43% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| COR Cencora, Inc. | 18.8× |
| HSIC Henry Schein, Inc. compare | 22.8× |
| MCK McKesson Corporation compare | 27.5× |
| CAH Cardinal Health, Inc. compare | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on COR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement